NICE High Cost Drugs - High Value Savings

Initiated Date	Primary or Secondary Care	Initiative	Description	Potential annual savings identified	Projected Savings 2024/25	Pharmacy Lead	Category		Apr-24	May-24	Jun-24	Jul-24	Aug-24	Sep-24	Oct-24	Nov-24	Dec-24	Jan-25	Feb-25	Mar-25	Total
Apr-24	Secondary Care	Infliximab	Change of biosimilar product from Inflectra (£80 per vial) to Flixabi (£55 per vial) in rheumatology	£48,000	£48,000	Alan Clatworthy	High Cost Drugs/ Nice	Projected Savings	£4,000	£4,000	£4,000	£4,000	£4,000	£4,000	£4,000	£4,000	£4,000	£4,000	£4,000	£4,000	£48,000
								Actual Savings	£4,049	£5,061	£2,371	£5,206	£3,644	£3,933	£4,338						£28,602
Nov-23	Secondary Care	Fingolimod (Gilenya®)	Switch from branded Gilenya to generic product. Homecare.	£150,000	£87,500	Charles Henry-Her / Grant Pearce	High Cost Drugs/ Nice	Projected Savings	£12,500	£12,500	£12,500	£12,500	£12,500	£12,500	£12,500						£87,500
								Actual Savings	£14,253	£16,925	£8,017	£11,580	£5,345	£10,690	£24,942						£91,752
Oct-23	Secondary Care	Apixaban	Introduction of new contract for Apixaban	£300,000	£150,000		High Cost Drugs/ Nice	Projected Savings	£25,000	£25,000	£25,000	£25,000	£25,000	£25,000							£150,000
								Actual Savings	£26,227	£30,302	£22,896	£31,290	£26,902	£27,352							£164,969
May-23	Secondary Care	Natalizumab	Price reduction to originator product	£340,000	£311,667		High Cost Drugs/ Nice	Projected Savings		£28,333	£28,333	£28,333	£28,333	£28,333	£28,333	£28,333	£28,333	£28,333	£28,333	£28,333	£311,667
								Actual Savings		£20,340	£26,442	£23,730	£31,526	£18,306	£34,917						£155,261
Oct-23	Secondary Care	Adalimumab	Switch to Hyrimoz (adalimumab biosimilar) for new patients (Rheumatology)	£36,000	£9,000		High Cost Drugs/ Nice	Projected Savings	£3,000	£3,000	£3,000	£0									£9,000
								Actual Savings	£5,628	£2,149	£3,048	£860									£11,685
Due to start November 2024	Secondary Care	Dimethyl Fumarate	Generic switch from Tecfidera in MS	£340,000			High Cost Drugs/ Nice	Projected Savings													£0
								Actual Savings													£0
TBC	Secondary Care	Infliximab	Change of biosimilar product from Inflectra (£80 per vial) to Flixabi (£55 per vial) in gastroenterology	£180,000			High Cost Drugs/ Nice	Projected Savings													£0
								Actual Savings													£0
Jul-24	Secondary Care	Pembrolizumab	Home Delivery and administration of Pembrolizumab	£24,000	£18,000		High Cost Drugs/ Nice	Projected Savings				£2,000	£2,000	£2,000	£2,000	£2,000	£2,000	£2,000	£2,000	£2,000	£18,000
								Actual Savings				£2,719	£1,145	£2,481	£3,268						£9,613
TBC - issues with availability	Secondary Care	Tocilizumab	Switch to Tyenne (tocilizumab biosimilar) in rheumatology	£180,000			High Cost Drugs/ Nice	Projected Savings													£0
								Actual Savings													£0
Oct-24	Secondary Care	Ustekinumab	Switch to biosimilar product when launched (Oct 2024). Gastro 49%; Derm 36%; Rheum 15%)	£1,000,000			High Cost Drugs/ Nice	Projected Savings													£0
								Actual Savings													£0
TBC - not yet available	Secondary Care	Pomalidamide	Switch to generic product (assuming 25% saving on current price paid)	£50,000			High Cost Drugs/ Nice	Projected Savings													£0
								Actual Savings													£0
Oct-24	Secondary Care	Bevacizumab	Switch to biosimilar product	£60,000	£30,000		High Cost Drugs/ Nice	Projected Savings							£5,000	£5,000	£5,000	£5,000	£5,000	£5,000	£30,000
								Actual Savings							£5,038						£5,038
TOTAL				£2,368,000	£654,167			Monthly Savings	£50,157	£74,777	£62,774	£75,385	£68,562	£62,762	£72,503	£0	£0	£0	£0	£0	£466,920
								Projected Savings	£44,500	£72,833	£72,833	£71,833	£71,833	£71,833	£51,833	£39,333	£39,333	£39,333	£39,333	£39,333	£654,167
								Actual Savings	£50,157	£74,777	£62,774	£75,385	£68,562	£62,762	£72,503	£0	£0	£0	£0	£0	£466,920

Secondary Care Savings (Non-NICE/High-Cost)

Initiated Date	Primary or Secondary Care	Initiative	Description	Potential annual savings identified	Projected Savings 2024/25	Pharmacy Lead	Category		Apr-24	May-24	Jun-24	Jul-24	Aug-24	Sep-24	Oct-24	Nov-24	Dec-24	Jan-25	Feb-25	Mar-25	Total
Dec-23	Secondary Care	Sugammadex	Contract for Sugammadex	£300,000	£200,000	Stuart W Evans	Secondary Care	Projected Savings	£25,000	£25,000	£25,000	£25,000	£25,000	£25,000	£25,000	£25,000					£200,000
								Actual Savings	£24,846	£34,508	£42,433	£44,912	£45,524	£54,275	£54,097						£300,595
Oct-24	Secondary Care	Melatonin liquid	Switch to Ceyesto	£36,000	£18,000	Stuart W Evans	Secondary Care	Projected Savings							£3,000	£3,000	£3,000	£3,000	£3,000	£3,000	£18,000
								Actual Savings							£3,536						£3,536
TOTAL				£300,000	£200,000			Monthly Savings	£24,846	£34,508	£42,433	£44,912	£45,524	£54,275	£57,633	£0	£0	£0	£0	£0	£304,131
								Projected Savings	£25,000	£25,000	£25,000	£25,000	£25,000	£25,000	£28,000	£28,000	£3,000	£3,000	£3,000	£3,000	£218,000
								Actual Savings	£24,846	£34,508	£42,433	£44,912	£45,524	£54,275	£57,633	£0	£0	£0	£0	£0	£304,131

Primary Care - Scriptswitch, workplan and optimisation

Initiated Date	Primary or Secondary Care	Initiative	Description	Potential annual savings identified	Projected Savings 2024/25	Pharmacy Lead	Category		Apr-24	May-24	Jun-24	Jul-24	Aug-24	Sep-24	Oct-24	Nov-24	Dec-24	Jan-25	Feb-25	Mar-25	Total
Apr-24	Primary Care	ScriptSwitch	Use of Prescribing Decision Support software to generate cost effective switches and formulary compliance	£720,000	£720,000	Rachel Howell	Primary Care	Projected Savings	£60,000	£60,000	£60,000	£60,000	£60,000	£60,000	£60,000	£60,000	£60,000	£60,000	£60,000	£60,000	£720,000
								Actual Savings	£86,910	£84,276	£107,307	£98,436	£86,908	£72,783	£71,183						£607,803
Apr-24	Primary Care	MM Workplan	General Workplan Carry over savings from 23-24 = £347,467	£787,467	£787,467	Rhys Howell	Primary Care	Projected Savings	£36,667	£36,667	£36,667	£36,667	£36,667	£36,667	£36,667	£36,667	£36,667	£36,667	£36,667	£36,667	£440,000
								Actual Savings	£87,180	£135,610	£85,242	£77,626	£65,021	£47,849	£81,987						£580,515
								Carry Over Savings	£0	£3,555	£5,499	£33,845	£54,151	£44,556	£37,715	£42,451	£15,338	£35,149	£36,453	£38,755	£347,467
Apr-24	Primary Care	Medicines Optimisation	Medicines optimisation Carry over savings from 23-24 £26,620	£83,000	£83,000	Rhys Howell	Primary Care	Projected Savings	£6,916	£6,916	£6,916	£6,916	£6,916	£6,916	£6,916	£6,916	£6,916	£6,916	£6,916	£6,916	£82,992
								Actual Savings	£1,640	£768	-£332	£702	-£2,102	£971	£80						£1,727
								Carry Over Savings	£42	£797	£5,286	£3,879	£4,215	£1,655	£2,932	£2,208	£3,427	-£1,691	-£117	£3,987	£26,620
TOTAL				£1,617,087	£1,617,087			Projected Savings	£103,583	£103,583	£103,583	£103,583	£103,583	£103,583	£103,583	£103,583	£103,583	£103,583	£103,583	£103,583	£1,242,992
								Actual Savings	£175,730	£220,654	£192,217	£176,764	£149,827	£121,603	£153,250	£0	£0	£0	£0	£0	£1,190,045
								Carry Over Savings	£42	£4,352	£10,785	£37,724	£58,366	£46,211	£40,647	£44,659	£18,765	£33,458	£36,336	£42,742	£374,087
								Total Savings	£175,772	£225,006	£203,002	£214,488	£208,193	£167,814	£193,897	£44,659	£18,765	£33,458	£36,336	£42,742	£1,564,132

Primary Care - individual drugs

Initiated Date	Primary or Secondary Care	Initiative	Description	Potential annual savings identified	Projected Savings 2024/25	Pharmacy Lead	Category		Apr-24	May-24	Jun-24	Jul-24	Aug-24	Sep-24	Oct-24	Nov-24	Dec-24	Jan-25	Feb-25	Mar-25	Total
Apr 24 to Sept 24	Primary Care	Loss of Exclusivity	Generic Sitagliptin - Cat M price reduction July 23- adjusted monthly (saving depends on Cat M, NCSO price changes etc.)	£240,000	£240,000	Rhys Howell	Primary Care	Projected Savings	£40,000	£40,000	£40,000	£40,000	£40,000	£40,000	£0	£0	£0	£0	£0	£0	£240,000
								Actual Savings	£44,391	£45,643	£49,280	£24,064	£27,338								£190,716
Apr 24 to Sept 24	Primary Care	Loss of Exclusivity	Generic Apixaban - Cat M price reduction July 23- Adjusted monthly (saving depends on Cat M, NCSO price changes etc.)	£2,000,000	£2,000,000	Rhys Howell	Primary Care	Projected Savings	£333,333	£333,333	£333,333	£333,333	£333,333	£333,333	£0	£0	£0	£0	£0	£0	£1,999,998
								Actual Savings	£353,469	£393,021	£404,933	£305,889	£233,293								£1,690,605
Sept 24 to Mar 25	Primary Care	Loss of Exclusivity	Generic Rivaroxaban - Cat M price reduction expected July 24 - Adjusted monthly	£700,000	£700,000	Rhys Howell	Primary Care	Projected Savings	£0	£0	£0	£0	£0	£100,000	£100,000	£100,000	£100,000	£100,000	£100,000	£100,000	£700,000
								Actual Savings	£0	£0	£0	£0	£0								£0
Apr 24 to Mar 26	Primary Care	Switch to Prasugrel	Ticagrelor to Prasugrel switch in Cardiology (24 months cost avoidance)	£345,000	£345,000	Rhys Howell	Primary Care	Projected Savings	£14,375	£14,375	£14,375	£14,375	£14,375	£14,375	£14,375	£14,375	£14,375	£14,375	£14,375	£14,375	£172,500
								Actual Savings	£0	£0	£0	£885	£3,896								£0
								Projected Savings	£387,708	£387,708	£387,708	£387,708	£387,708	£487,708	£114,375	£114,375	£114,375	£114,375	£114,375	£114,375	£3,112,498
								Actual Savings	£397,860	£438,664	£454,213	£330,838	£264,527	£0	£0	£0	£0	£0	£0	£0	£1,881,321